Business

Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as follows: Title: Pain mitigation in pancreatic adenocarcinoma: A long-term

articleAutonomix Medical, Inc.December 18, 20252/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-announces-abstract-133000146
Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

About this update from Autonomix Medical, Inc.

[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA.","length":389,"tagName":"p"},{"type":"text","content":"Details of the poster presentation are as follows:","length":50,"tagName":"p"},{"type":"text","content":"Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablationAbstract Number: 693Presenter: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Date and Time: January 9, 2026 from 11:30 AM-1:00 PM and 5:00 PM-6:00 PM PST","length":419,"tagName":"p"},{"type":"text","content":"About ASCO","length":10,"tagName":"p"},{"type":"text","content":"Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum.","length":614,"tagName":"p"},{"type":"text","content":"About Autonomix Medical, Inc. ","length":29,"tagName":"p"},{"type":"text","c...

More updates from Autonomix Medical, Inc.

Autonomix Medical, Incposter presentationASCOAutonomix Medical, Inc.Poster SessionRobert S. Schwartz